Literature DB >> 8944104

Congenital nasolacrimal duct obstruction in the second year of life: a multicentre trial of management.

J D Young1, C J MacEwen, S A Ogston.   

Abstract

We studied spontaneous resolution of congenital nasolacrimal duct obstruction in the second year of life and compared this with the cure rate after probings undertaken between the ages of 11 and 15 months. Of the 111 eyes of 95 patients studied, 26 eyes were included in a randomised prospective comparison of probing with spontaneous resolution. A further 63 eyes followed a similar management plan to the randomised group and are reported as an observational study. Thirty of the 50 eyes followed up without treatment resolved spontaneously before the age of 2 years, of which 24 resolved before 18 months. The overall cure rate for probing was 74% compared with 60% for spontaneous resolution. At 15 months of age the randomised study confirmed that probing at 12-14 months is an effective intervention compared with spontaneous resolution (p = 0.04). At 24 months of age probing was superior in both randomised and non-randomised studies, but with increased numbers in the spontaneous resolution groups the difference was no longer statistically significant. Up to 18 months of age the frequency of spontaneous resolution makes delay in probing a viable management option to be discussed with the parents. It will also lead to an overestimate of the cure rate in any study of interventional treatment unless controls are included.

Entities:  

Mesh:

Year:  1996        PMID: 8944104     DOI: 10.1038/eye.1996.107

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  15 in total

1.  Value of nasal endoscopy and probing in the diagnosis and management of children with congenital epiphora.

Authors:  C J MacEwen; J D Young; C W Barras; B Ram; P S White
Journal:  Br J Ophthalmol       Date:  2001-03       Impact factor: 4.638

2.  Long-term results of probing guided with soft cannula in children with congenital nasolacrimal duct obstruction.

Authors:  Dilek Yuksel; Pınar Altiaylik Ozer
Journal:  Jpn J Ophthalmol       Date:  2013-11-16       Impact factor: 2.447

3.  Ophthaproblem. Congenital nasolacrimal duct obstruction.

Authors:  S Sharma
Journal:  Can Fam Physician       Date:  1998-10       Impact factor: 3.275

Review 4.  Probing for congenital nasolacrimal duct obstruction.

Authors:  Carisa Petris; Don Liu
Journal:  Cochrane Database Syst Rev       Date:  2017-07-12

5.  Pediatric nasolacrimal duct obstruction-benefit of a combined therapeutic approach.

Authors:  Miloš Fischer; Iris-Susanne Horn; Mathias Otto; Mandy Pirlich; Andreas Dietz; Christian Mozet
Journal:  World J Pediatr       Date:  2017-05-24       Impact factor: 2.764

6.  Probing for congenital nasolacrimal duct obstruction in older children.

Authors:  Bahram Eshragi; Masoud Aghsaei Fard; Babak Masomian; Mohammadreza Akbari
Journal:  Middle East Afr J Ophthalmol       Date:  2013 Oct-Dec

Review 7.  Systematic review to determine whether participation in a trial influences outcome.

Authors:  Gunn Elisabeth Vist; Kåre Birger Hagen; P J Devereaux; Dianne Bryant; Doris Tove Kristoffersen; Andrew David Oxman
Journal:  BMJ       Date:  2005-05-21

8.  Paediatric endoscopic endonasal dacryocystorhinostomy in congenital nasolacrimal duct obstruction.

Authors:  Igal Leibovitch; Dinesh Selva; Angelo Tsirbas; Edward Greenrod; John Pater; Peter J Wormald
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-03-15       Impact factor: 3.117

9.  Efficacy of probing for children with congenital nasolacrimal duct obstruction: a retrospective study using fluorescein dye disappearance test and lacrimal sac echography.

Authors:  Piero Steindler; Enrico Mantovani; Carlo Incorvaia; Francesco Parmeggiani
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-12-24       Impact factor: 3.117

10.  Late and very late initial probing for congenital nasolacrimal duct obstruction: what is the cause of failure?

Authors:  M B Kashkouli; B Beigi; M M Parvaresh; A Kassaee; Z Tabatabaee
Journal:  Br J Ophthalmol       Date:  2003-09       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.